Drug Discovery Today: how the transition from preclinical research to clinical trials can impact biotech valuations

A recent study published in Drug Discovery Today by Thomas Thurston and Hubert Truebel found low odds of success for biotech startups that raise more than four funding rounds before starting their clinical trials. Highlights: Analysis of 233 biotech startups at various stages, and - separately - 238 biotech startups that were ultimately acquired or had and IPO. There was…

0 Comments

Watch recording of Thomas Thurston’s talk at IIEX (Insight Innovation Exchange)

If you weren't able to make it to the virtual IIEX Conference (Insight Innovation Exchange), you can watch a recording of Thomas's presentation right here! https://events.greenbook.org/iiex-north-america/agenda/session/321871 How Big Data Insights are Disrupting Venture Capital Learn how a leading venture capital firm is using big data and AI to identify disruptive startups worldwide. By using data and statistics to disrupt the…

0 Comments

Thomas Thurston speaking at IIEX (Insight Innovation Exchange) Sept. 10, 2020

How Big Data Insights are Disrupting Venture Capital Learn how a leading venture capital firm is using big data and AI to identify disruptive startups worldwide. By using data and statistics to disrupt the way traditional venture capital has been done, the firm is seeing more wins and fewer losses while dramatically reducing costs.  It’s also changing what it means…

0 Comments

Shedding New Light on Intelligent Investment Strategies

"When it comes to successfully identifying the likely success of companies, and steering an effective investment strategy, there is one organization that appears to be well ahead of the pack. The company is WR Hambrecht and the person guiding their analysis and decision-making process utilizing a proprietary software system he developed more than a decade ago is Thomas Thurston, Partner…

0 Comments

Clayton Christensen and the Predictive Nature of Profit-Seeking

Clayton Christensen was exceptional, both personally and professionally. He impacted the world on many levels, and today I’d like to focus on how a narrow aspect of his work has proven to be amongst the most profound: profit-seeking. At its most basic, Christensen restated what we already know – businesses want to make money. (Although that’s sort of like saying…

0 Comments

Reflections on Deep Learning, DNNs, and AI on Wall Street

In this special guest feature, Bob Fletcher from Verne Global reflects on the recent HPC and AI on Wall Street conference.  "While obviously the New York financial community was the focus for this conference one of the best presentations came from out-of-town. Thomas Thurston, CTO at San Francisco based WR Hambrecht Ventures shared an amazing use case for DNN training.…

0 Comments

How Hambrecht Uses Machine Learning to Up its Venture Hit Rate 3X

Venture capital is a “hit business.” The relatively few hits pay for the flops. And it's the tantalizing possibility of a mega-hit that animates the industry, that keeps investors dreaming, prospecting and writing checks. For venture capitalists, it’s the hits and the mega-hits that make the high flop rate tolerable. But is frequent venture failure inescapable? Could a probabilistic approach…

0 Comments

Hambrecht Ducera Growth Ventures leads $15M funding round for Buoy Health

Boston-based online diagnostic platform Buoy Health has recently announced the details of its Series B funding round. Buoy is a revolutionary health platform powered by advanced AI and offers users medical support in real time. “Based on our proprietary MESE™ models, Buoy’s impact relative to the amount of money they’ve raised is astounding, and we’re very bullish on their future,”…

0 Comments

No more articles

No more pages to load